New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’ By: MarketWatch December 09, 2022 at 10:50 AM EST Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study. Read More >> Related Stocks: Biogen Idec
